Full text
Earnings transcript
Read the complete earnings call transcript.
ANGO
AngioDynamics, Inc.
$10.31
-1.63
(-13.65%)
| Exchange: | NASDAQ |
| Market Cap: | 424.951M |
| Shares Outstanding: | 9.2M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Instruments & Supplies | |||||
| CEO: | James C. Clemmer | |||||
| Full Time Employees: | 748 | |||||
| Address: |
| |||||
| Website: | https://www.angiodynamics.com |
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon’s, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 338,752 | 303,914 | 292,498 |
| Gross Profit | 174,246 | 154,698 | 157,705 |
| EBITDA | 12,194 | -6,132 | 1,738 |
| Operating Income | -51,181 | -192,435 | -39,954 |
| Net Income | -52,442 | -184,349 | -33,993 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 532,637 | 317,671 | 280,144 |
| Total Liabilities | 154,341 | 112,085 | 97,174 |
| Total Stockholders Equity | 378,296 | 205,586 | 182,970 |
| Total Debt | 49,818 | 5,914 | 0 |
| Cash and Cash Equivalents | 44,620 | 76,056 | 55,893 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 78 | -28,158 | -10,808 |
| Capital Expenditure | -4,352 | -5,768 | -4,464 |
| Free Cash Flow | -4,274 | -33,926 | -15,272 |
| Net Income | -52,442 | -184,349 | -33,993 |
| Net Change in Cash | 15,795 | 31,436 | -20,163 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 389,191.797 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 393,824.581 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 391,639 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 5,942.547 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 6,013.284 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 5,979.913 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 11,788.638 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 11,971.426 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 11,885.360 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 172,948.201 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 175,006.908 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 174,035.684 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 0.290 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 0.290 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 0.290 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 1 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 1 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
At what price to buy it? -
Intrinsic Value Calculator
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about ANGO valuation
Is ANGO (ANGO) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for ANGO (ANGO) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is ANGO a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether ANGO trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is ANGO’s P/E ratio?
You can see ANGO’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for ANGO?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is ANGO a good long-term investment?
Whether ANGO fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
ANGO
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
-13.65
Trading Metrics:
| Open: | Previous Close: | |||
| Day Low: | Day High: | |||
| Year Low: | Year High: | |||
| Price Avg 50: | Price Avg 200: | |||
| Volume: | Average Volume: |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free
Relevant news
